Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

3(60.0%)

Phase 1

1(20.0%)

Phase 2

1(20.0%)

5Total

Phase 4(3)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06077656Phase 2Completed

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

Role: collaborator

NCT07097012Phase 4Recruiting

Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy

Role: collaborator

NCT07275060Phase 4Active Not Recruiting

Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart

Role: collaborator

NCT06915779Completed

Long Term Follow-up of HPV Vaccine in HIV (CTN 236)

Role: collaborator

NCT03753347Phase 4Active Not Recruiting

TITRE III: Influenza B Immunogenicity Investigation

Role: collaborator

NCT05540028Phase 1Completed

Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

Role: collaborator

All 6 trials loaded